Pharmacologic properties of the new oral anticoagulants: A clinician-oriented review with a focus on perioperative management

Current Pharmaceutical Design

Volumn 16, Issue 31, 2010, Pages 3436-3441

  Douketis, James D ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

New anticoagulants; Perioperative anticoagulation; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; CLARITHROMYCIN; DABIGATRAN; DABIGATRAN ETEXILATE; FONDAPARINUX; HEPARIN; HYPERICUM PERFORATUM EXTRACT; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; NEW DRUG; QUINIDINE; RIFAMPICIN; RITONAVIR; RIVAROXABAN; TENOFOVIR; VERAPAMIL; VORICONAZOLE;

ANTICOAGULATION; ARTICLE; BLEEDING; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG HALF LIFE; HUMAN; PERIOPERATIVE PERIOD; PHARMACODYNAMICS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; DRUG INTERACTIONS; DRUGS, INVESTIGATIONAL; HUMANS; MORPHOLINES; PERIOPERATIVE CARE; PYRAZOLES; PYRIDONES; THIOPHENES;

EID: 78649980897     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793563338     Document Type: Article

References (44)

1. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009; 48 (1): 1-22.
2. Sobieraj-Teague M, O'Donnell M, Eikelboom J. New anticoagulants for atrial fibrillation. Semin Thromb Hemost 2009; 35: 515-524.
3. Apostolakis S, Lip GY, Lane DA, Shantsila E. The quest for new anticoagulants: From clinical development to clinical practice. Cardiovasc Ther 2010 DOI: 10.1111/j.1755-5922.2010.00160.x.
4. Samama MM, Gerotziafas GT. Newer anticoagulants in 2009. J Thromb Thrombolysis 2010; 29 (1): 92-104.
5. Hauel NH, Nar H, Priepke H, et al. Structure-based design of novelpotent nonpeptide thrombin inhibitors. J Med Chem 2002; 45 (9): 1757-1766.
6. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. In-vitro profile and ex vivo anticoagulanr activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007; 98 (1): 155-162.
7. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Phar-macokinet 2008; 47 (5): 285-295.
8. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12): 1139-1151.
9. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus war- farin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361 (24): 2342-52.
10. Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36 (2): 386-399.
11. Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64 (3): 292-303.
12. Stangier J, Stahle H, Rathgen K, et al. Pharmokinetics and phar-macodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47 (1): 47-59.
13. Liesenfeld KH, Schafer HG, Troconiz IF, et al. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopedic surgery patients: a population model analysis. Br J Clin Pharmacol 2006; 62 (5): 527-537.
14. Castellone DD, Van Cott EM. Laboratory monitoring of new anticoagulants. Am J Hematol 2010; 85: 185-187.
15. Stangier J, Stahle H, Rathgen K, et al. The pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thromo-bin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol 2008; 48(12): 1411-1419.
16. Rezaie AR. Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex. Blood 2001; 97 (8): 2308-2313.
17. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel ntithrombotic agent BAY 59-7939-an oral, direct factor Xa inhibitor. J Thromb Haemost 2005; 3 (3): 514-521.
18. Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78 (4): 412-421.
19. Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynam-ics, and pharmacokinetics of BAY 59-7939 - an oral, direct factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873-880.
20. Weinz C, Radtke M, Schmeer K, et al. In vitro metabolism of BAY 59-7939 - an oral, direct factor Xa inhibitor (abstract no. 195). Drug Metab Rev 2004; 36 (Suppl. 1): 98.
21. Gross PL, Weitz JL. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 2008 28 (3): 380-386.
22. Mueck W, Borris LC, Dahl OE, et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008; 100 (3): 453-461.
23. Mueck W, Eriksson BI, Bauer KA, et al. Population pharmacoki-netics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor - in patients undergoing major orthopedic surgery. Clin Pharmacokinet 2008; 47 (3): 203-216.
24. Gerotziafas GT, Elalamy I, Depasse F, et al. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost 2007; (4): 886-888.
25. Graff J, von Hentig N, Misselwitz F, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 2007; 47(11): 1398-1407.
26. Graff J, Picard-Willems B, Harder S. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a. Int J Clin Pharmacol Ther 2007; 45 (4): 237-243.
27. Frost C, Yu Z, Nepal S, et al. Apixaban, a direct factor Xa inhibitor: single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation. J Clin Pharmacol 2008; 48 (9): 1132.
28. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics following oral administration to humans. Drug Metab Dispos 2009; 37(1): 74-81.
29. Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost 2006; 96 (3): 274-284.
30. Eriksson BI, Dahl OE, Büller HR, et al. A new oral direct throm-bin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3: 103-111.
31. Eikelboom JW, Weitz JI. Dabigatran etexilate for prevention of venous thromboembolism. Thromb Haemost 2009; 101: 2-4.
32. Eriksson BI, Dahl OE, Rosencher N, et al. RE-NOVATE study group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement; a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956.
33. Eriksson BI, Dahl OE, Rosencher N, et al. RE-MODEL study group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5(11): 2178-2185.
34. Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009; 101: 77-85.
35. Eriksson BI, Borris LC, Friedman RJ, et al. RECORD-1 STUDY GROUP. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-1775.
36. Kakkar AK, Brenner B, Dahl OE, et al. RECORD-2 INVESTIGATORS. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-39.
37. Lassen MR, Ageno W, Borris LC, et al. RECORD-3 investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786.
38. Turpie AG, Lassen MR, Davidson BL, et al. RECORD-4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty: a randomised trial. Lancet 2009; 373: 1673-80.
39. th Edition). Chest 2008; 133: 299S-339S.
40. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
41. Samama MM, Martinoli JL, LeFlem L, et al. Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 103: 815-825.
42. Agnelli G, Sonaglia F, Becattini C. Direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery. Curr Pharm Des 2005; 11(30): 3885-3891.
43. Alban S. Pharmacological strategies for inhibition of thrombin activity. Curr Pharm Des 2008; 14(12): 1152-1175.
44. Barantke M, Bonnemeier H. Factor Xa inactivation in acute coronary syndrome. Curr Pharm Des 2008; 14(12): 1186-1190.